Contact Us
Drug Search Results
More Filters [+]

BI-3032950

Alternative Names: BI-3032950, BI 3032950, BI3032950
Latest Update: 2025-01-25
Latest Update Note: Clinical Trial Update

Product Description

BI-3032950 is a drug candidate being developed by Boehringer Ingelheim. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05518708?term=BI-3032950&draw=2&rank=1)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BI-3032950

Countries in Clinic: Belgium, Czech Republic, Poland, Slovakia, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Colitis, Ulcerative

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
1486-0006

P2

Unknown Status

Colitis, Ulcerative

2028-08-03

U1111-1300-3640

P2

Recruiting

Colitis, Ulcerative

2026-05-11

U1111-1289-1904

P1

Completed

Healthy Volunteers

2024-08-19

NCT05518708

P1

Completed

Healthy Volunteers

2023-09-21

28%

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions